| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 45,642 | 34,964 | 36,402 | 43,606 |
| Loss from operations | -34,412 | -28,501 | -29,164 | -28,244 |
| Interest and other income, net | 2,246 | 2,481 | 2,842 | 3,578 |
| Total other income, net | 2,246 | 2,481 | 2,842 | 3,578 |
| Loss before income taxes | -32,166 | -26,020 | -26,322 | -24,666 |
| Net loss | -32,166 | -26,020 | -26,322 | -24,666 |
| Unrealized loss on marketable securities | - | -73 | -10 | 895 |
| Unrealized gain on marketable securities | 117 | - | - | - |
| Comprehensive loss | -32,049 | -26,093 | -26,332 | -23,771 |
| Net loss per share basic (in dollars per share) | -0.44 | -0.37 | -0.37 | -0.35 |
| Net loss per share diluted (in dollars per share) | -0.44 | -0.37 | -0.37 | -0.35 |
| Weighted-average number of shares used in computed net loss per share basic | 72,563,311 | 71,005,743 | 70,833,044 | 69,627,190 |
| Weighted-average number of shares used in computed net loss per share diluted | 72,563,311 | 71,005,743 | 70,833,044 | 69,627,190 |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)